Importantly, depleting or inhibiting USP13 sensitizes ovarian cancer cells to cisplatin and Poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib) suggesting USP13 is a potential novel therapeutic target for ovarian cancer. This evidence concerns the gene USP13 and ovarian cancer.